27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases
Responses were accompanied by decreases in levels of carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) and improvement in clinical symptoms
Read more at globenewswire.comXILIO THERAPEUTICS INC
NASDAQ:XLO (2/12/2025, 8:00:03 PM)
After market: 1.3501 -0.13 (-8.78%)1.48
+0.82 (+125.27%)
8 hours ago - ChartmillKeep an eye on the top gainers and losers in Wednesday's session.Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
9 hours ago - ChartmillThese stocks are the most active in today's sessionLet's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.
10 hours ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
12 hours ago - ChartmillTraders are paying attention to the gapping stocks in Wednesday's session.The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.
